News

Patent "Selective Nox-1 inhibitor peptides and uses thereof" whose licence has been attributed to ProGeLife by SATT Aquitaine Transfert has been delivered in USA under N° US10517919

Patent " Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer" co-owned by ProGeLife has been granted by European Patent Office (EPO) under reference EP3244909

[FranceBleu] "Children of the Moon" discovered a night dive in Annecy lake

They are around a hundred in France and about 100,000 worldwide. Children and young adults are affected by a rare genetic disease, called "Children of the Moon" disease. They exhibit an extreme skin sensitivity to sun exposure.

FranceBleu web site : https://www.francebleu.fr/infos/sante-sciences/les-enfants-de-la-lune-decouvrent-la-plongee-subaquatique-en-nocturne-au-lac-d-annecy-1566750139

Night dive in Marseille's bay by Children of the Moon

"Children of the Moon" crossed Marseille's bay till Frioul islands during afretnoon, through Moultiploufs association.

The boat trip, just above the water line using Moultiploufs Association dinghies, ended at sunset. Child could then remove helmet and gloves and feel high happiness by experiencing wind, sea breeze and sprays. That was for some of them a "grande première".

Then, children made a night dive, each of them closely surrounded by two Moultiploufs divers.

https://moultiploufs.com/

https://www.youtube.com/watch?v=En7H-GDr8HY

[AGENCY PRESS] : ANNECY : ProGeLife diving with the "Children of the Moon"

On August 23 and 24, 9 young patients from the " Children of the Moon " association participated in a night dive at Annecy Lake and benefited from the anti-stress therapeutic protocol of the start-up Bathysmed.

Read more on :

http://www.presseagence.fr/lettre-economique-politique-paca/2019/09/01/annecy-progelife-en-plongee-avec-les-enfants-de-la-lune/

https://www.bathysmed.fr/

ProGeLife participated to the International Symposium on XP and other nucleotide excision repair disorders

Organized by Robert Sarkany, member of ProGeLife Scientific Advisory Board, the symposium took place in Cambridge (UK) from 20th to 22th of march 2019.

Eric Dessaud, Head of Clinical Development and Sophie Perrin, Research Project Leader, participated in the meeting, gathering more than 100 specialists, from clinicians, to molecular biologists and geneticians.

ProGeLife participes to the General meeting of the french association "Children of the Moon" in Bellegarde sur Valsérine

Frédéric Bénéton became ProGeLife CEO

Patent "Selective Nox-1 inhibitor peptides and uses thereof" whose licence has been attributed to ProGeLife by SATT Aquitaine Transfert has been delivered in Tunisia under N° 24558

ProGeLife participates to Recherch'Thon for the second year

  • In a 100 m2 tent close to the Ombrière on Marseille's old port. Friday 8th december from 14h to 19h and saturday 9th december from 10h to 19h; in parallel to Téléthon manisfestations.
  • The goal of this event is that all research laboratories funded by Téléthon met the public and explain how donations are used.
  • As a start-up issued from academic research, ProGeLife is well committed to this event. Our company shows a goose game, allowing to describe all the steps required for the development of a drug, especially for the treatment of rare diseases.
  • Several exhibition stands are animated by researchers, medical doctors, ingeneers and geneticians showing the journey of a patient suffering of a genetic disease.
  • Medical consultation, DNA sampling, biological assyays, medical imagin and therapeutic trials are described in a fun way and in an welcoming and friendly atmosphere.

PGL101 peptide received "Orphan Drug Designation" (ODD) from the FDA (US Food and Drug Administration) for the treatment of Xeroderma pigmentosum

The team led by Professor Nicolas Lévy published the discovery of a new molecule for the treatment of progeria in EMBO Molecular Medicine scientific journal

 

ProGeLife gets 730,000 euros from Bpifrance (innovation aid - ADI) for the development of PGL101 peptide in the prevention and treatment of skin cancers.

  • The repayable interest-free advance obtained from Bpifrance will finance part of the development of InhNOX1-O1 topical formulation to fight against ultraviolet (UV) induced skin cancers in Xeroderma pigmentosum patients and in elderly. “This 730,000€ innovation aid is a crucial step for ProGeLife. It will enable us to accelerate the development of InhNOX1-O1 topical formulation and initiate the preclinical regulatory studies required prior clinical trials”, said Pr. Nicolas Lévy (CMO) from ProGeLife. “We wish to thank Bpifrance for its recognition of  PGL101 program.”
  • About Xeroderma pigmentosum ("Children of the moon disease"): XP is a rare genetic disease characterized by a hypersensitivity of the skin to sun and UV radiation, leading to skin and ocular lesions and an increased risk of skin cancers. There is no therapeutic drug yet available to prevent and/or treat skin lesions observed in XP patients.
  • About InhNOX1-O1 peptide: PGL101 (InhNOX1-O1) peptide is a specific inhibitor of NADPH oxidase 1 (NOX1), an enzymatic complex involved in the formation of Reactive Oxygen Species (ROS), e.g. in the skin following UV-exposure. The inhibitory effect of PGL101 was demonstrated in both in vitro and in vivo models. Proof of efficacy for the prevention and treatment of skin tumors was obtained in XPC-disease model.  PGL101 peptide was granted an Orphan Drug Designation (ODD) from the EMA "for the prevention and treatment of skin cancers in XP patients" in 2014.

ProGeLife participates to the Health Future Show organized by Interpro Santé Provence (UP13) and Eurobiomed

  • The meeting, whose topic was "Tomorrow health is invented today", selected 30 French and US biotechs, among them ProGeLife, that are developing innovations in health field and exposed in the Innovation Village. (http://www.upe13.com/component/content/article/91-oneshot/3328-le-village-de-l-innovation&Itemid=)

ProGeLife participates to the European Xeroderma pigmentosum Society (EXPS) meeting

  • EXPS is a subgroup of the European Association of Dermatology and Venerology (EADV, https://www.eadv.org/) and associates European dermatologists specialized in Xeroderma pigmentosum disease (XP) and the European patient support groups. The EXPS meets every year during EADV congresses and invites international experts in the field of XP disease to address clinical (standard of care, retrospective and prospective studies, case studies, etc.) and non-clinical (academic research and patient support groups) aspects.

Eric Dessaud joins ProGeLife as Head of Clinical Development

  • Eric Dessaud completed a Ph.D. (Developmental Biology Institute of Marseille, FR) and a post-doctoral fellowship in Neurobiology (National Institute for Medical Research, UK). He enriched is background with education in statistics for medical research (DIU CESAM, FR). He joined the Institut Paoli Calmettes (Marseilles, FR) as a Clinical Research Associate and monitored Clinical Studies from Phase I to Phase III in oncology.
  • Eric held a position of International Clinical Project Manager during 6 years at TROPHOS, a French Biotech recently acquired by ROCHE. He managed European Clinical Studies for rare diseases (Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy).
  • Eric skills in all aspects of clinical development represent an invaluable advantage for ProGeLife.

ProGeLife raises 1.3M€ from private investors

  • The financing of 1,315,000€ from private investors will fund the development of InhNOX1-O1 topical formulation to fight against skin cancers in Xeroderma pigmentosum patients and in aged people. “We are delighted to be able to share our vision and our development program with a group of investors, who recognized the innovative aspect of our approach”, explained the co-founder of ProGeLife, Pr. Nicolas Lévy (CMO). “This is a major step for pursuing our activities and initiate InhNOX1-O1 program.”
  • About Xeroderma pigmentosum ("Children of the moon disease"): XP is a rare genetic disease characterized by a hypersensitivity of the skin to sun and UV radiation, leading to skin and ocular lesions and an increased risk of skin cancers. There is no therapeutic drug yet available to prevent and/or treat skin lesions observed in XP patients.
  • About PGL101 (InhNOX1-O1) peptide: InhNOX1-O1 peptide is a specific inhibitor of NADPH oxidase 1 (NOX1), an enzymatic complex involved in the formation of Reactive Oxygen Species (ROS), e.g. in the skin following UV-exposure. The inhibitory effect of peptide was demonstrated in both in vitro and in vivo models. Proof of efficacy for the prevention and treatment of skin tumors was obtained in XPC-disease model. InhNOX1-O1 peptide was granted an Orphan Drug Designation (ODD) from the EMA "for the prevention and treatment of skin cancers in XP patients" in 2014.

ProGeLife hires a skilled engineer, Pascale Klopp, to strengthen his R&D team

  • Pascale holds a M.S. in Biotechnology from Strasburg University. She brings a 10 years engineering experience between private (Syngenta AG) and academic laboratories (INSERM UMR1048, Toulouse, France). She acquired valuable technical skills Next-Generation Sequencing, qPCR assays, cell biology and mice handling. 
  • Multidisciplinary skills of Pascale constitute a precious advantage for the development of ProGeLife activities.

ProGeLife strengthens his team with Gaëlle Odelin, Doctor in Veterinary Medicine (DVM) , PhD, as research project leader

  • Graduated from the Ecole Nationale Vétérinaire (Toulouse, FR) and former intern in medicine and surgery (VetAgro Sup, Toulouse, FR), Gaëlle exercised as a veterinary practitioner for two years. In 2010, she joined Dr Zaffran’s team (INSERM UMR_S910) for her master and her PhD on the study of mouse models of cardiovascular diseases. Her dual expertise, as veterinarian and researcher, that Gaëlle acquired during her studies, is a key asset for the development of ProGeLife’s projects.

ProGeLife obtained a financial help from Impulse Incubator

http://incubateur-impulse.fr/Products/162/ProGeLife

ProGeLife is selected to the First international biotechnology meeting (Rencontres Internationales de Biotechnologies, RIB 2015)

  • The first international biotechnology meeting dedicated to rare diseases was held today at Bpifrance -Le Hub, hosted by Leem and Bpifrance. This forum has facilitated connections between biotech startups and major pharmaceutical companies and has helped accelerate the development of partnerships between actors of the innovation chain. The morning sessions opened with pitches to introduce the 16 selected companies and were followed in the afternoon by 85 B-to -B meetings between biotechs and pharma companies.
  • http://www.leem.org/sites/default/files/PR%202015-07-03-RIB.pdf
  • http://www.leem.org/sites/default/files/RIB_2015.pdf

ProGeLife completes his team by hiring Héloïse Laroye as Clinical Research Coordinator

  • Postgraduate in Nutrition, Heloïse has developed skills since 2005 as a Clinical Researcher Assistant and Clinical Research Coordinator. She worked in fields of diabetes, cardiology, nutrition and cancer.
  • Heloïse has ensured the development, monitoring and/or coordination of 15 clinical research phase III and IV studies and in the fields of drug product, telemedicine, medical devices, care and epidemiology. She worked on missions of project management and operational, and she acquired the competence to work in the various stages of a project.
  • Her knowledge in biomedical research will allow her to succeed in her tasks for ProGeLife projects.

ProGeLife working on UV-induced skin aging and cancer

 

The "children of the moon" finally see a hope of treatment. The start-up ProGeLife, founded in June 2015 has just signed a licensing agreement with SATT Aquitaine Science Transfert. It will enable it to exploit the peptide InhNOX1-O1 patented by the INSERM 1035 team of Professor Alain Taïeb, University of Bordeaux.

 

ProGeLife signs an exclusive licensing agreement with Aquitaine Science Transfert for the development of InhNOX technology in health domain.

ProGeLife generates his R&D team through the hiring of two PhD biologists, Sophie Perrin and Claire Navarro, as research project leader.

  • Claire was involved in the discovery of the mutation responsible of progeria in 2003, then of another progeroid syndrome, restrictive dermopathy, in 2004 and 2005. After her a PhD (Eukaryote Biology) in 2007, Claire has been actively involved in several in vivo studies on a progeria mice model, in the identification of mutations in new premature aging syndromes, and in the development of treatments of these disorders.
  • Sophie obtained her PhD in human pathology in 2012, after graduate in 2008 from the Superior Engineering School Polytech Marseille. Thanks to her university and professional background, she is a cell biology scientist with experience going from academic to industrial drug discovery research, with first insight to various health fields (rare genetic disorders, Infectious disease, oncology, aging). Sophie is particularly interested in remaining at the interface between basic research and therapeutics applications.
  • Claire and Sophie are co-inventors of one patent describing a drug for the treatment of progeria and other rare diseases whose ProGeLife is co-owner. Sophie and Claire skills represent a strong resource for ProGeLife.

PGL101 (InhNOX1) peptide get from EMA the designation of "Orphan Drug Designation" (ODD) for the prevention and the treatment of Xeroderma pigmentosum disease.

  • Xeroderma pigmentosum ("Children of the moon disease") is a rare genetic disease characterized by an extremely high skin sensitivity to sun and UV radiation, with an increasing risk of skin cancers. 

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp

ProGeLife is founded by Nicolas Lévy (MD, PhD, Professor in Medical Genetics, Hospital Practitioner), Pierre Cau (MD, PhD, Professor in Cell Biology, Hospital Practitioner) and several associates.

  • ProGeLife is a biotechnology R&D company, whose goal is the development of therapeutic solutions dedicated for rare genetic diseases characterized by premature or accelerated aging. The same solution can further be applied to age-related diseases affecting the whole population.
  • ProGeLife is funded under the Law 99-587 "Innovation and Research" in order to exploit patent licenses from academia, particularly those whose Nicolas Lévy and Pierre Cau are inventors.